Document is current
Any future updates will be listed below
-
Authors
Maas-Bauer, Kristina
Kiote-Schmidt, Chrissoula
Bertz, Hartmut
Apostolova, Petya
Wäsch, Ralph https://orcid.org/0000-0002-0813-3444
Ihorst, Gabriele https://orcid.org/0000-0002-8091-1589
Finke, Jürgen
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
- License Information
-
More Information
Article History
Received: 5 June 2020
Revised: 25 September 2020
Accepted: 29 October 2020
First Online: 17 November 2020
Compliance with ethical standards
:
: RZ received speakers fees from Incyte, Novartis, and Mallinckroth. The other authors have no conflict of interest with this manuscript to disclose.
: The analysis of soluble IL2R was approved by the ethics committee of the University Medical Center Freiburg, ethics approval number: 547/14. Ruxolitinib and ECP are used in clinical routine for cGVHD treatment based on multiple reports showing efficacy. Prior to treatment with ruxolitinib and ECP informed consent was obtained from each patient.
